Quick Answer
BridgeBio Pharma, Inc. reported Operating Income of -$523.41 million for fiscal year 2025.
BridgeBio Pharma, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$523.41M | +11.7% |
| 2024 | -$592.97M | +2.4% |
| 2023 | -$607.37M | -18.6% |
| 2022 | -$512.20M | +11.2% |
| 2021 | -$576.63M | -21.5% |
| 2020 | -$474.48M | -78.2% |
| 2019 | -$266.24M | -45.0% |
| 2018 | -$183.66M | -318.8% |
| 2017 | -$43.86M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$145.20M | +24.3% | -8.1% |
| June 30, 2025 | -$134.28M | +23.5% | -28.7% |
| March 31, 2025 | -$104.37M | -30529.2% | +45.6% |
| September 30, 2024 | -$191.75M | -21.6% | -9.2% |
| June 30, 2024 | -$175.54M | -20.2% | -51277.6% |
| March 31, 2024 | $343.0K | +100.3% | +100.2% |
| September 30, 2023 | -$157.69M | -22.1% | -7.9% |
| June 30, 2023 | -$146.10M | -82.2% | -15.8% |
- BridgeBio Pharma, Inc. showed an increase of +11.7% in Operating Income compared to the prior fiscal year.
- Over the 2017–2025 period, BridgeBio Pharma, Inc.’s operating income has declined by 1093.4% (from -$43.86 million to -$523.41 million).
- The most recent figure is from BridgeBio Pharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: